Co-Authors
This is a "connection" page, showing publications co-authored by Jordan Elm and Yuko Palesch.
Connection Strength
0.678
-
Screen failure data in clinical trials: Are screening logs worth it? Clin Trials. 2014 Aug; 11(4):467-472.
Score: 0.126
-
Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke. 2013 Aug; 8(6):479-83.
Score: 0.119
-
Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial. J Biopharm Stat. 2012; 22(4):758-72.
Score: 0.107
-
A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
Score: 0.066
-
Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis. JAMA Netw Open. 2019 09 04; 2(9):e1910769.
Score: 0.045
-
Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. JAMA Neurol. 2019 07 01; 76(7):774-782.
Score: 0.045
-
Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke. Circulation. 2019 08 20; 140(8):658-664.
Score: 0.045
-
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018 Jul 19; 379(3):215-225.
Score: 0.041
-
An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project. Ann Emerg Med. 2012 Oct; 60(4):451-7.
Score: 0.027
-
Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord. 2009 Sep 15; 24(12):1732-9.
Score: 0.023
-
Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology. 2006 Mar 14; 66(5):628-33.
Score: 0.018
-
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
Score: 0.016